[Post-licensure passive safety surveillance of rotavirus vaccines: reporting sensitivity for intussusception].
نویسندگان
چکیده
INTRODUCTION The aims of this study were to describe the reports of suspected adverse events due to rotavirus vaccines, and assess the reporting sensitivity for intussusception. MATERIAL AND METHODS Descriptive study performed using the reports of suspected adverse events following rotavirus vaccination in infants aged less than 10 months, as registered in the Pharmacovigilance Centre of the Valencian Community during 2007-2011. The reporting rate for intussusception was compared to the intussusception rate in vaccinated infants obtained using the hospital discharge database (CMBD), and the regional vaccine registry. RESULTS The adverse event reporting rate was 20 per 100,000 administered doses, with the majority (74%) of the reports being classified as non-serious. Fever, vomiting, and diarrhea were the adverse events reported more frequently. Two intussusception cases, which occurred within the first seven days post-vaccination, were reported as temporarily associated to vaccination. The reporting sensitivity for intussusception at the Pharmacovigilance Centre in the 1-7 day interval following rotavirus vaccination was 50%. CONCLUSIONS Our results suggest that rotavirus vaccines have, in general, a good safety profile. Intussusception reporting to the Pharmacovigilance Centre shows sensitivity similar to other passive surveillance systems. The intussusception risk should be further investigated using well-designed epidemiological studies, and evaluated in comparison with the well-known benefits provided by these vaccines.
منابع مشابه
Rotavirus vaccination and intussusception – Science, surveillance, and safety: A review of evidence and recommendations for future research priorities in low and middle income countries
As of January 2016, 80 countries have introduced rotavirus vaccines into their national immunization programs. Many have documented significant declines in rotavirus-specific and all-cause diarrheal illnesses following vaccine introduction. Two globally licensed rotavirus vaccines have been associated with a low risk of intussusception in several studies. In July 2014, the Rotavirus Organizatio...
متن کاملResults after one year of rotavirus universal mass vaccination in Sicily
Background Rotavirus (RV) vaccination is the best strategy to prevent hospitalizations due to rotavirus gastroenteritis (RVGE) and is strongly recommended by international health authority [1]. The Sicilian Health Department introduced rotavirus universal mass vaccination (RUMV) into regional immunizations schedule in 2013 (mean vaccination coverage = 31%). Intussusception is the invagination o...
متن کاملIntussusception risk with 116E rotavirus vaccine in Vellore, South India.
We congratulate John and colleagues for their surveillance of ntussusception during the 116E rotavirus vaccine trial [1]. They oint out that it is critical to be vigilant to the risk of intussusception to determine if there are safety signals of a larger magnitude than urrently expected that may preclude licensure”. Rotasheild was licensed after a trial involving 14,687 patients. n this trial t...
متن کاملEnhancing vaccine safety surveillance: a capture-recapture analysis of intussusception after rotavirus vaccination.
The Vaccine Adverse Event Reporting System (VAERS) is the passive reporting system for postmarketing surveillance of vaccine safety in the United States. The proportion of cases of an adverse event after vaccination that are reported to VAERS (i.e., VAERS reporting completeness) is mostly unknown. Therefore, the risk of such an event cannot be derived from VAERS only. To study whether its repor...
متن کاملValue of post-licensure data on benefits and risks of vaccination to inform vaccine policy: The example of rotavirus vaccines.
In 1999, the first rhesus-human reassortant rotavirus vaccine licensed in the United States was withdrawn within a year of its introduction after it was linked with intussusception at a rate of ∼1 excess case per 10,000 vaccinated infants. While clinical trials of 60,000-70,000 infants of each of the two current live oral rotavirus vaccines, RotaTeq (RV5) and Rotarix (RV1), did not find an asso...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Anales de pediatria
دوره 81 2 شماره
صفحات -
تاریخ انتشار 2014